Halozyme Therapeutics, Inc.
HALO
$71.48
$0.751.06%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -16.61% | 27.52% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -16.61% | 27.52% | |||
| Cost of Revenue | -5.30% | 52.66% | |||
| Gross Profit | -20.28% | 21.06% | |||
| SG&A Expenses | -8.60% | 37.41% | |||
| Depreciation & Amortization | 26.25% | 31.61% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.62% | 44.76% | |||
| Operating Income | -27.47% | 16.74% | |||
| Income Before Tax | 278.81% | -146.06% | |||
| Income Tax Expenses | -25.68% | -6.84% | |||
| Earnings from Continuing Operations | 205.97% | -180.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 205.97% | -180.81% | |||
| EBIT | -27.47% | 16.74% | |||
| EBITDA | -22.73% | 17.83% | |||
| EPS Basic | 205.55% | -180.49% | |||
| Normalized Basic EPS | -28.62% | 14.45% | |||
| EPS Diluted | 201.39% | -184.15% | |||
| Normalized Diluted EPS | -31.37% | 19.44% | |||
| Average Basic Shares Outstanding | 0.40% | 0.39% | |||
| Average Diluted Shares Outstanding | 4.42% | -3.81% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||